Overview
In its March 2026 draft guidance, the US Food and Drug Administration (FDA) outlined its current thinking on how drug and certain product manufacturers should approach Form 483 responses to inspectional observations issued at the conclusion of a current good manufacturing practice (CGMP) inspection. The FDA emphasized that Form 483s reflect inspectional observations rather than final compliance determinations, but noted that a manufacturer’s response may serve as a key input into the agency’s assessment of whether further regulatory action is warranted. The draft guidance provides recommendations regarding the content, format, and timing of responses to Form 483 when manufacturers choose to submit them.
The FDA will accept comments from industry and the public on the draft guidance through May 8, 2026.
In Depth
Background
FDA Form 483s are issued when FDA investigators observe conditions or practices that, in their judgment, may constitute violations of the Federal Food, Drug, and Cosmetic Act. Form 483 provides notice to the inspected establishment of significant inspectional observations identified during the inspection, but it does not represent the FDA’s final compliance determination or an enforcement decision.
Consistent with long-standing CGMP requirements, drug manufacturers remain responsible for investigating and correcting deficiencies and ensuring ongoing compliance, regardless of whether they submit a written response to a Form 483 or receive feedback from the FDA. The draft guidance is intended to promote clear and effective communication between the FDA and industry and to clarify the agency’s current thinking on best practices for responding to inspectional observations, including how manufacturers should assess risk, conduct investigations, and implement and evaluate corrective and preventive actions.
The guidance applies to domestic and foreign manufacturers of human and animal drugs regulated by the FDA’s Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Veterinary Medicine (CVM), as well as certain combination product manufacturers where CDER or CBER is the lead center. While the guidance is focused on these product areas, many of the principles discussed may also be useful when responding to Form 483 observations for other product areas or when preparing responses to FDA warning letters.
Why it matters
Recent FDA enforcement actions reflect increasing scrutiny of both inspectional findings and manufacturers’ post inspection responses. For example, FDA warning letters often reference Form 483 responses and consider the adequacy of those responses when evaluating whether inspectional observations have been addressed, including whether manufacturers have identified root causes, provided supporting documentation, and implemented corrective actions. Where the FDA has identified repeat or unresolved observations, the agency has characterized such issues as indicative of systemic compliance failures, which could increase the likelihood of enforcement escalation.
Submitting a response to Form 483
The draft guidance reiterates the FDA’s recommendation that establishments submit a single comprehensive written response within 15 business days of the Form 483 issuance. The FDA explains that responses received within this timeframe are generally reviewed in detail before the agency determines whether to pursue subsequent regulatory action, whereas responses submitted after 15 business days may not delay enforcement action.
The FDA further recommends that Form 483 responses be accurate, clear, concise, and well organized and demonstrate that the establishment is addressing, or actively working to address, both the specific observations and the underlying issues that led to them. The guidance identifies core elements that should be included in a written response, such as:
- Identification of the inspected establishment (including facility information and FDA establishment identifier)
- A copy of the Form 483
- Identification of the response preparer and signatory
- An executive summary describing remediation activities and associated corrective actions.
Investigations and risk assessment
The draft guidance places significant emphasis on robust, scientifically justified investigations. The FDA recommends that establishments develop written investigation plans that clearly define scope, methodology, and a risk based rationale, including justification for any operations, products, or facilities excluded from the investigation.
The FDA further advises that investigations extend beyond the specific observation cited to assess whether identified deficiencies may affect other drugs or batches, manufacturing processes or systems, additional facilities, or contract manufacturing or testing organizations. In conducting these assessments, manufacturers are encouraged to evaluate trends, prior inspection findings, and internal audit results to determine whether observations reflect broader or systemic issues. The agency cautions that addressing only the most apparent or immediate cause of an observation may be insufficient and may not prevent recurrence.
The guidance also underscores the importance of patient and product focused risk assessments, including evaluation of inventory and distributed drugs still within expiry and any potential impact on safety, identity, strength, quality, or purity.
CAPA development and effectiveness
The FDA encourages manufacturers to begin developing corrective and preventive action (CAPA) plans during or immediately following the inspection, with plans further refined as investigations progress. CAPAs should be commensurate with the level of risk identified and structured to address root causes, rather than symptoms, of observed deficiencies.
According to the guidance, effective CAPA plans should include:
- Defined timelines and measurable milestones
- Interim control measures, where remediation cannot be completed promptly
- Clear deliverables
- Communication plans for providing follow up updates to the FDA.
CAPAs should be implemented across all affected areas, and manufacturers are expected to verify that CAPAs are effective and do not result in unintended consequences. The FDA emphasizes that evaluation of CAPA effectiveness is a critical component of compliance, noting that routine testing alone may be insufficient. Where effectiveness checks are inadequate, manufacturers may need to revisit root cause analyses and CAPA strategies. FDA notes that it may verify CAPA implementation and effectiveness during subsequent inspections.
Management responsibility and oversight
The draft guidance highlights management’s central role in responding to Form 483 observations. The FDA expects management to review inspectional observations at both the facility and corporate levels, ensure appropriate allocation of resources, and support multidisciplinary investigation teams. Although manufacturers may engage consultants, the FDA emphasizes that ultimate responsibility for CGMP compliance remains with the establishment.
The FDA recommends that management consider why deficiencies were not previously identified or addressed by the quality system and assess whether improvements to quality culture, governance, or oversight mechanisms are necessary to prevent future issues.
Resolving scientific or technical disagreements
Where scientific or technical disagreements arise, the FDA encourages establishments to seek clarification during the inspection and to document unresolved issues in the written response. Responses should clearly describe the contested facts and provide supporting scientific data, as well as references to applicable statutes, regulations, or FDA guidance.
The draft guidance also identifies the FDA’s formal dispute resolution processes and the Office of the Ombudsman as potential avenues for further escalation when disagreements cannot be resolved through the inspection or response process.
Next steps
Drug and product manufacturers may wish to review their post‑inspection procedures and internal escalation frameworks in light of the FDA’s draft guidance, including timelines for response preparation, investigation planning, and executive management review. Establishments may also consider whether their current approaches to root cause analysis, CAPA development, and effectiveness evaluation align with the FDA’s articulated expectations. Companies should evaluate whether to submit comments on the draft guidance to the FDA by the May 8, 2026, deadline.
The McDermott difference
McDermott Will & Schulte will continue to monitor the FDA’s finalization and implementation of this guidance and its broader enforcement posture with respect to CGMP inspections. If you have questions about how this draft guidance may affect your inspection response strategy, please contact a member of our Food, Drug & Medical Device Group.